Maximilian Yosri Emmert

Dr. Maximilian Yosri Emmert


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VPVanesa Palau
Vanesa Palau
Bramasta NugrahaBramasta Nugraha
Bramasta Nugraha
DBDavid Benito
David Benito
JPJulio Pascual
Julio Pascual
MEMaximilian Yosri Emmert
Maximilian Yosri Emmert
MSMaria Jose Soler
Maria Jose Soler
ADAM17 is a disintegrin and metalloproteinase capable of cleaving the ectodomains of a diverse variety of molecules including TNF-α, TGF-α, L-selectin, and ACE2. We have previously demonstrated that renal ADAM17 is upregulated in diabetic mice. The role of endothelial (eAdam17) and proximal tubular (tAdam17) Adam17 deletion in renal histology, modulation of the renin angiotensin system (RAS), renal inflammation, and fibrosis was studied in a mouse model of type 1 Diabetes Mellitus. Moreover, the effect of Adam17 deletion in an in vitro 3D cell culture from human proximal tubular cells under high glucose conditions was evaluated. eAdam17 deletion attenuates renal fibrosis and inflammation, whereas tAdam17 deletion decreases podocyte loss, attenuates the RAS, and decreases macrophage infiltration, α-SMA and collagen accumulation. The 3D in vitro cell culture reinforced the findings obtained in tAdam17KO mice with decreased fibrosis in the Adam17 knockout spheroids. In conclusion, Adam17 deletion either in the endothelial or the tubular cells mitigates kidney injury in the diabetic mice by targeting different pathways. The manipulation of Adam17 should be considered as a therapeutic strategy for treating DN.

4 April 2025 in Biomechanics and Modeling in Mechanobiology
Verified
Journal Article
Open access
PDF file
VVValery L. Visser
Valery L. Visser
SMSarah E. Motta
Sarah E. Motta
SHSimon P. Hoerstrup
Simon P. Hoerstrup
FBFrank P. T. Baaijens
Frank P. T. Baaijens
SLSandra Loerakker
Sandra Loerakker
MEMaximilian Yosri Emmert
Maximilian Yosri Emmert
Tissue-engineered heart valves (TEHVs) are promising valve replacements due to their potential to regenerate into living heart valves, capable of growth and adaptation. Previous TEHVs showed promising results, but often developed progressive leaflet retraction in the long term. In a prior proof-of-concept study, we demonstrated that a novel geometry with more native-like mechanical behavior could give rise to more adaptive remodeling, thereby minimizing leaflet retraction in vivo. In the current study, we aimed to systematically analyze the impact of TEHV geometry on in vivo remodeling under both pulmonary and aortic conditions. Using a bio-inspired in silico framework, we predicted cell-driven, mechano-mediated remodeling in TEHVs post-implantation. Two parameterized valve designs were evaluated under both pulmonary and aortic pressure conditions. The results indicate that a valve design with smooth leaflets, a curved belly profile, and medium to wide attachment edge effectively minimizes stress concentrations and reduces the risk of valve insufficiency in both conditions. Additionally, this design should be tailored to specific hemodynamic conditions to prevent retraction in pulmonary applications and excessive stress concentrations in aortic applications. These insights provide essential guidelines for optimizing TEHV designs, aiming to promote functional remodeling and maintain valve functionality over time, thereby advancing the development of next-generation TEHVs with enhanced long-term outcomes.

19 March 2025 in Acta Biomaterialia
Verified
Journal Article
Open access
PBPascal Breitenstein
Pascal Breitenstein
VVValery L. Visser
Valery L. Visser
SMSarah E. Motta
Sarah E. Motta
Marcy MartinMarcy Martin
Marcy Martin
MGMelanie Generali
Melanie Generali
MEMaximilian Yosri Emmert
Maximilian Yosri Emmert
Cardiovascular disease remains one of the leading causes of mortality in the Western world. Congenital heart disease affects nearly 1 % of newborns, with approximately one-fourth requiring reconstructive surgery during their lifetime. Current cardiovascular replacement options have significant limitations. Their inability to grow poses particular challenges for pediatric patients. Tissue Engineered Matrix (TEM)-based in situ constructs, with their self-repair and growth potential, offer a promising solution to overcome the limitations of current clinically used replacement options. Various functionalization strategies, involving the integration of biomechanical or biochemical components to enhance biocompatibility, have been developed for Tissue Engineered Vascular Grafts (TEVG) and Tissue Engineered Heart Valves (TEHV) to foster their capacity for in vivo remodeling. In this review, we present the current state of clinical translation for TEVG and TEHV, and provide a comprehensive overview of biomechanical and biochemical functionalization strategies for TEVG and TEHV. We discuss the rationale for functionalization, the implementation of functionalization cues in TEM-based TEVG and TEHV, and the interrelatedness of biomechanical and biochemical cues in the in vivo response. Finally, we address the challenges associated with functionalization and discuss how interdisciplinary research, especially when combined with in silico models, could enhance the translation of these strategies into clinical applications. STATEMENT OF SIGNIFICANCE: Cardiovascular disease remains one of the leading causes of mortality, with current replacements being unable to grow and regenerate. In this review, we present the current state of clinical translation for tissue engineered vascular grafts (TEVG) and heart valves (TEHV). Particularly, we discuss the rationale and implementation for functionalization cues in tissue engineered matrix-based TEVGs and TEHVs, and for the first time we introduce the interrelatedness of biomechanical and biochemical cues in the in-vivo response. These insights pave the way for next-generation cardiovascular implants that promise better durability, biocompatibility, and growth potential. Finally, we address the challenges associated with functionalization and discuss how interdisciplinary research, especially when combined with in silico models, could enhance the translation of these strategies into clinical applications .

28 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MKMichelle Klein
Michelle Klein
AEArian Ehterami
Arian Ehterami
NRNeguin Ranjbar
Neguin Ranjbar
SHSimon P. Hoerstrup
Simon P. Hoerstrup
MEMaximilian Yosri Emmert
Maximilian Yosri Emmert
MGMelanie Generali
Melanie Generali
Background: The extracellular matrix (ECM) plays a central role in the mechanical strength and functional integration of tissue-engineered matrix (TEM), particularly in cardiovascular and load-bearing applications. Mesenchymal stromal cells (MSCs) from different sources may vary in their ECM-forming potential. Methods: In this study, adipose-derived (hADMSC), bone marrow-derived (hBMSC), and umbilical cord-derived MSCs (hUCMSC) were compared with human dermal fibroblasts (HDFBs) as a reference. Cells were seeded onto polyglycolic acid (PGA)/poly-4-hydroxybutyrate (P4HB) scaffolds and cultured for 3 weeks under static or hydrodynamic conditions using orbital shaking. TEM development was assessed macroscopically, histologically (using H&E and Masson’s trichrome stains), and by polarized light microscopy (Picrosirius Red), alongside biochemical assays that quantified DNA, glycosaminoglycan (GAGs), and hydroxyproline (HYP). Results: Hydrodynamically stimulated culture consistently improved ECM deposition across all groups. TEMs exposed to hydrodynamic stimulation (hydrodynamic conditions) were thicker, more uniformly filled, and exhibited increased collagen deposition compared with static TEMs, which remained thinner and showed persistent scaffold remnants. Polarized light analysis demonstrated that dynamic loading promoted collagen maturation in all groups, as evidenced by an increased prevalence of thick, birefringent collagen fibers indicative of mature collagen. Biochemical analyses showed that HDFB-derived TEMs produced the highest total collagen and ECM content under both static and hydrodynamic conditions; however, these matrices remained comparatively thin and densely packed. In contrast, MSC-derived TEMs formed thicker and more spatially distributed ECM in response to hydrodynamic stimulation. Conclusion: Among the MSC sources, hUCDMSC-derived TEMs exhibited the most advanced collagen maturation and the most uniform collagen distribution under hydrodynamically stimulated culture, whereas hADMSC-derived TEMs showed the greatest matrix thickening and volumetric ECM expansion with intermediate collagen maturation. hBMSC-derived TEMs displayed clear responsiveness to hydrodynamic stimulation but remained limited in overall collagen deposition and fiber maturation. These findings underscore that both hydrodynamic stimulation and cell source are critical not only for maximizing ECM deposition, but also for ensuring physiologically relevant collagen maturation and matrix organization in grafts suitable for clinical translation.

Verified
Journal Article
Open access
PDF file
ILIsabel Lavanchy
Isabel Lavanchy
LPLaina Passos
Laina Passos
TAThierry Aymard
Thierry Aymard
JGJürg Grünenfelder
Jürg Grünenfelder
MEMaximilian Yosri Emmert
Maximilian Yosri Emmert
DRDiana Reser
Diana Reser
Background: Little is known about gender-dependent outcomes after aortic valve replacement (AVR) through right anterior thoracotomy (RAST). The aim of our study was to analyze the mid-term outcomes of our cohort. Methods: This study is a retrospective analysis of 338 patients (2013–2022). Subgroup analysis included a gender-dependent comparison of age groups ≤60 and >60 years. Results: Women were older (69.27 ± 7.98 vs. 64.15 ± 11.47, p < 0.001) with higher Euroscore II (1.25 ± 0.73 vs. 0.94 ± 0.45, p < 0.001). Bypass and cross-clamp time were shorter (109.36 ± 30.8 vs. 117.65 ± 33.1 minutes, p = 0.01; 68.26 ± 21.5 vs. 74.36 ± 23.3 minutes, p = 0.01), while ICU, hospital stay and atrial fibrillation were higher (2.48 ± 8.2 vs. 1.35 ± 1.4 days, p = 0.005; 11 ± 7.8 vs. 9.48 ± 2.3 days, p = 0.002; 6.7% vs. 4.4%, p = 0.024). Mortality was 0.9%, while stroke was 0.6%. Age subgroup analysis showed that women were older (p = 0.025) with longer ICU and hospital stays (p < 0.001, p = 0.007). On mid-term follow-up (4.52 ± 2.67 years) of 315 patients (94.3%), there was no significant difference in survival, MACCE and re-intervention comparing gender and age groups. Conclusions: Despite older age, higher Euroscore II, longer ICU and hospital stay in women, mortality, MACCE and reoperation were low and comparable in gender and age groups. We believe that our patient-tailored heart team decision making combined with RAST translates into gender-tailored medicine, which equalizes the widely reported negative outcomes of female patients after cardiac surgery.